Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

被引：0
|
作者：
Zeqing Zhang
Xi Chen
Puhan Lu
Jianhua Zhang
Yongping Xu
Wentao He
Mengni Li
Shujun Zhang
Jing Jia
Shiying Shao
Junhui Xie
Yan Yang
Xuefeng Yu
机构：
[1] Huazhong University of Science and Technology,Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Glucagon-like peptide-1 agonists; Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes mellitus; Cardiovascular outcomes; Acute pancreatitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
    Kutz, Alexander
    Kim, Dae Hyun
    Wexler, Deborah J.
    Liu, Jun
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Patorno, Elisabetta
    DIABETES CARE, 2023, 46 (11) : 2004 - 2014
  • [22] Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor
    Higashi, Yukihito
    JOURNAL OF CARDIOLOGY, 2017, 69 (3-4) : 508 - 510
  • [23] Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists-A Network Meta-analysis
    Roddick, Alistair J.
    Zheng, Sean
    DIABETES, 2018, 67
  • [24] Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
    Vasiliki Bistola
    Vaia Lambadiari
    George Dimitriadis
    Ioannis Ioannidis
    Konstantinos Makrilakis
    Nikolaos Tentolouris
    Apostolos Tsapas
    John Parissis
    Heart Failure Reviews, 2018, 23 : 377 - 388
  • [25] Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
    Bistola, Vasiliki
    Lambadiari, Vaia
    Dimitriadis, George
    Ioannidis, Ioannis
    Makrilakis, Konstantinos
    Tentolouris, Nikolaos
    Tsapas, Apostolos
    Parissis, John
    HEART FAILURE REVIEWS, 2018, 23 (03) : 377 - 388
  • [26] DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi, S.
    DIABETES & METABOLISM, 2008, 34 : S91 - S95
  • [27] The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Dara L. Eckerle Mize
    Marzieh Salehi
    Current Diabetes Reports, 2013, 13 : 307 - 318
  • [28] Mortality Differences SGLT-2, DPP-4 Inhibitors and GLP-1 Receptor Agonists
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (03): : 173 - 173
  • [29] Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis
    Evans, Marc
    Kuodi, Paul
    Akunna, Chisom Joyqueenet
    Mccreedy, Nicole
    Donsmark, Morten
    Ren, Hongye
    Nnaji, Chukwudi A.
    DIABETES & VASCULAR DISEASE RESEARCH, 2023, 20 (06):
  • [30] SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization
    Lyu, Beini
    Grams, Morgan
    Chang, Alex R.
    Inker, Lesley A.
    Coresh, Josef
    Shin, Jung-Im
    DIABETES, 2021, 70
12345